Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

Inclusion Criteria: * Fasting LDL-C ≥100 mg/dL * High cardiovascular risk (diagnosis of HeFH and/or ASCVD) * Be on maximally tolerated lipid-modifying therapy (LMT), including maximally tolerated statin either alone or in combination with other LMTs Exclusion Criteria: * Total fasting triglyceride ≥500 mg/dL * Renal dysfunction or nephrotic syndrome or history of nephritis * Body Mass Index (BMI) ≥50kg/m2 * Significant cardiovascular disease or cardiovascular event in the past 3 months